Permanent Injunction Issued Preventing Launch of EYLEA® Biosimilar Yesafili™

On June 11, 2024, the Court in Case No. 1:22-cv-00061 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.) issued a permanent injunction against the launch of Biocon and Mylan’s Yesafili™ (aflibercept-jbvf), a recently approved interchangeable biosimilar of Regeneron’s EYLEA® (aflibercept) (previously reported FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon’s Yesafili™ (aflibercept-jbvf) and Samsung Bioepis’s Opuviz™ (aflibercept-yszy))….
By: Venable LLP
Previous Story

Auto Parts supplier obtains defense verdict at trial

Next Story

Update on Aflibercept BPCIA Litigation